Tripeptide-29
Also known as: Collagen Tripeptide, GHK Mimic
Molecular Identifiers
Overview
Synthetic tripeptide that mimics collagen fragments, stimulating type I collagen production in the dermis. Sequence based on repetitive motifs of the collagen alpha chain.
Tripeptide-29 is developed as a mimetic of collagen fragments, signaling dermal fibroblasts to stimulate type I collagen synthesis. The expected effect is improved skin elasticity and reinforcement of the dermal barrier, with continuous use. It is often combined with other peptides such as Matrixyl and Argireline in multi-peptide formulations to enhance the anti-aging effect.
Today it is used almost exclusively as a cosmetic ingredient, at typical concentrations of 50 to 200 ppm in serums, creams, and professional formulations sold over the counter. It has no approval as a medicine and is not given by injection. The exact structure may vary between manufacturers, which makes direct product-to-product comparison difficult.
Among cosmetic peptides, Tripeptide-29 is mechanistically close to Matrixyl: both signal fibroblasts to increase collagen synthesis, with no neuromuscular action. It differs fundamentally from Argireline, SNAP-8, and Acetyl Octapeptide-1 (which act on the SNARE pathway) and from Decapeptide-12 (depigmentation). As a simple and inexpensive tripeptide, it is often used as a complementary ingredient in formulations that already contain Matrixyl or SNARE-group peptides.
GPO Collagen motif-based tripeptide. Structure varies between manufacturers.
Half-life
Variable (topical use)
Administration Route
Topical
Category
Cosmetic & Skin
Mechanism of Action
- Stimulation of type I collagen synthesis
- Signaling to dermal fibroblasts
- Improvement of skin elasticity
- Strengthening of the dermal barrier
Dosage Protocol
Data compiled from the literature. This does not constitute medical advice.
| Parameter | Value |
|---|---|
| Dose | Topical application |
| Frequency | 1-2 times daily |
| Timing | Morning and/or evening |
| Duration | Continuous use |
Reported Side Effects
Adverse effects described in the literature. Severity and frequency vary between individuals.
- Mild skin irritation (very rare)
Product Properties
| Purity | >98% |
| Appearance | White lyophilized powder |
| Solubility | Soluble in water and bacteriostatic water |
| Source | Solid-phase peptide synthesis (SPPS) |
| Storage | Lyophilized: -20°C for up to 2 years, 2-8°C for up to 6 months. Reconstituted: 2-8°C for up to 4 weeks. Protect from light and moisture. Avoid repeated freeze-thaw cycles. |
Presentations & Preparation
Vials of Tripeptide-29 found in the research market:
Reconstitution
- Diluent: N/A (topical use)
- Volume: N/A
- Supplied as powder or incorporated into formulations
- Typical concentration 50-200 ppm
Storage
- Lyophilized: Room temperature
- Reconstituted: N/A
- Protect from light
- Store in a cool, dry place
Scientific Studies
Published studies on Tripeptide-29.
Related Peptides
Acetyl Octapeptide-1
Topical 3-5% · Twice daily
AHK-Cu
Topical or 200-500 mcg subcutaneous · 1-2 times daily (topical), every other day (subcutaneous)
Argireline
Topical 5-10% or 100-250 mcg subcutaneous · Topical twice daily, subcutaneous 2-3x per week
Decapeptide-12
Topical application · 1-2 times daily
GHK Basic
Topical or 200-600 mcg subcutaneous · 1-2 times daily (topical), every other day (subcutaneous)
Matrixyl
Topical application · 1-2 times daily